Management of post-COVID-19 olfactory dysfunction

Tara J. Wu1
Alice C. Yu1
Jivianne T. Lee1,*

Address
1,2Department of Head and Neck Surgery, David Geffen School of Medicine at the University of California, Los Angeles (UCLA), 10833 Le Conte Avenue, 62-132 CHS, Los Angeles, CA 90095, USA
Email: JTLee@mednet.ucla.edu

This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply 2021

Abstract
Purpose of Review Olfactory dysfunction is a frequent complication of SARS-CoV-2 infection. This review presents the current literature regarding the management of post-COVID-19 olfactory dysfunction (PCOD).

Recent Findings A systematic review of the literature using the PubMed/MEDLINE, EMBASE, and Cochrane databases for the following keywords, “Covid-19,” “SARS-CoV-2,” “anosmia,” “olfactory,” “treatment,” and “management” was performed. While most cases of post-COVID-19 olfactory dysfunction resolve spontaneously within 2 weeks of symptom onset, patients with symptoms that persist past 2 weeks require medical management. The intervention with the greatest degree of supporting evidence is olfactory training, wherein patients are repeatedly exposed to potent olfactory stimuli. To date, no large-scale randomized clinical trials exist that examine the efficacy of pharmacologic therapies for PCOD. Limited clinical trials and prospective controlled trials suggest intranasal corticosteroids and oral corticosteroids may alleviate symptoms.

Summary Olfactory training should be initiated as soon as possible for patients with PCOD. Patients may benefit from a limited intranasal or oral corticosteroid course. Further research on effective pharmacologic therapies for PCOD is required to manage the growing number of patients with this condition.
Introduction

Post-coronavirus disease 2019 (COVID-19) olfactory dysfunction (PCOD) is thought to occur as a result of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) damaging the olfactory neuroepithelium [1, 2]. Several studies have hypothesized that this damage is mediated by viral invasion of ACEII and TMPRSS2 receptors on cells in the nasal and olfactory epithelium [3–5]. MRI studies have shown co-occurrence of transient olfactory bulb edema with PCOD, suggesting that an inflammatory response to this viral invasion may contribute to symptomatology as well [6].

Anosmia often represents the first or only symptom of COVID-19 disease, and it is estimated to be present in 19–68% of patients, often independently of coryzal symptoms [2, 7–9]. Any degree of olfactory dysfunction (OD) is estimated to be present in a larger majority, with up to 85–98% of patients affected in some studies [1, 2]. The natural course of PCOD is spontaneous resolution by two weeks for 95% of patients, with mean recovery of 9 days [9, 10]. However, in some patients, persistent PCOD is a prevalent symptom, appearing in 75% of cases with persistent COVID symptoms [11]. Risk factors for persistent PCOD include older age, diabetes mellitus, and longer duration of COVID-19 illness [9]. In light of the global prevalence of COVID-19, even a small proportion of patients with PCOD likely numbers in the millions. Physicians face the challenge of managing an unprecedented number of patients with PCOD in the coming years.

The impacts of PCOD on quality of life are significant. PCOD reduces a person’s ability to enjoy foods and fragrances, recall olfaction-associated memories, and detect hazardous materials such as spoiled food and toxic fumes [12]. Furthermore, it is associated with a range of debilitating psychosocial effects, including depression, social isolation, impaired cognition, decreased nutrition, and earlier death [13•].

There is strong evidence supporting the use of olfactory training (OT) in the management of PCOD, with most studies demonstrating greater improvements in olfactory function (OF) with earlier initiation of therapy [13•, 14••]. However, there has been no consensus on appropriate pharmacotherapy for treatment of PCOD. Some limited randomized control trials have demonstrated benefit with short-term topical or oral corticosteroid use, but to date, there have been no large-scale trials investigating their efficacy [15–18]. Other therapies used in non-COVID-19 OD, such as theophylline, vitamin A, omega-3, or zinc, have been investigated but lack compelling evidence in favor of their use [19••].

The following studies employed a variety of olfactory tests to assess OF in response to treatment. Some studies used the Sniffin’ Sticks test, which uses felt-tip pens to present various concentrations of odorants to assess a subject’s odor threshold, discrimination, and identification. In this test, OF is measured using the threshold, discrimination, and identification (TDI) score [20]. The University of Pennsylvania Smell Identification Test (UPSIT) is another widely used, well-validated olfactory test, in which a subject is asked to identify 40 scratch-and-sniff odors in a test booklet [21]. Other tests include the objective Connecticut Chemosensory Clinical Research Center (CCCRC) test as described by Cain et al. [22] and the subjective Visual Analog Scale (VAS) as described by McCormack et al. [23]. In all of these tests, higher scores indicated better OF.

Treatment

Diet and Lifestyle

For patients with PCOD, counseling should be provided to maximize quality of life, nutrition, and safety. Patients should be strongly encouraged to ensure proper functioning of smoke and natural gas detectors to facilitate early detection of warning smells [24], class 2A. They should also be advised to exercise...
caution in food safety by monitoring food expiration dates as well as to monitor overall nutritional intake [24], class 2A. In active smokers, smoking cessation has been suggested to improve olfactory symptoms in patients with post-infectious olfactory disorders (PIOD) [19••], class 2A. Traditional Chinese acupuncture has also been studied in limited low-level studies (1 level 3 study; 1 level 4 study), showing clinically significant improvements in TDI and UPSIT scores among a small group of patients with minimal treatment-related risk [13•], class 4.

Patients with OD have also demonstrated higher rates of depression than normosmic patients, suggesting a need for early recognition, screening, and intervention including referral to mental health services when appropriate [24], class 2A.

### First-Line Therapy

#### Olfactory Training

The therapy for treatment of PCOD with the greatest evidentiary support is olfactory training (OT). OT is a non-pharmacologic treatment option involving repeated odor exposure, with promising outcomes for treatment of PVOD [Table 1]. The mechanism of action for this therapy is largely hypothetical but is thought to be related to regeneration of olfactory receptor neurons and/or improved higher order processing of olfactory information [25], level 4. A position paper by Hummel et al. recommended OT in patients with olfactory loss of several etiologies, given the demonstrated benefits seen in several studies [26], level 5.

Classical OT protocols include twice-daily exposure to a set of 4 intense odors, including rose, eucalyptus, lemon, and cloves over a period of 12 weeks [20], level 2B. In the morning and evening, patients smell each odorant for 10 s, rotating through all 4 odors to finish the set. Since the inception of OT, modified OT protocols have allowed patients to purchase their own essentials oils with varying odor concentrations and combinations, which have been shown to increase patient compliance and adherence while still achieving clinically significant improvements in olfactory function [14••], level 2A; 28, level 2B. Modified OT protocols have tested a wider variety of odors and longer durations of therapy with improved outcomes [14••], level 2A; 25, level 4. Conversely, therapy durations of less than 12 weeks may be ineffective [17], level 2B.

Denis et al. described a trial wherein 548 participants underwent olfactory training with concurrent visual depictions of the scents. After 4 weeks, 64% of patients reported improved symptoms [27], level 1B. Though this study was limited by the lack of a control cohort, the results demonstrated that a large proportion of patients experienced clinically significant benefit from OT. Several meta-analyses published by Hura et al., Kattar et al., and Addison et al. all came to similar conclusions, as evidenced in Table 1 [13•], level 1A; 14••, level 2A; 19••, level 2A. Hura et al. reviewed 10 studies, including 5 randomized controlled trials (RCTs), which demonstrated that OT resulted in
| Study/year                  | Level of evidence | Study design                                                                 | Results                                                                                                                                                                                                 | Conclusions                                                                                                                                                                                                 |
|----------------------------|------------------|-----------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Studies on PCOD            |                  |                                                                             |                                                                                                                                                                                                         |                                                                                                                                                                                                           |
| Denis et al. 2021 [27]     | 1B               | - 548 patients with at least 1 month of PCOD were exposed to OT twice daily assisted by a web application displaying pictures correlated with the odorants for at least 7 days | - 64% of patients showed a clinically significant improvement after a mean olfactory training of 28 days  
- Patients who trained for longer than 28 days experienced better outcomes  
- Hyposmic patients exhibited improved outcomes after OT compared to anosmic patients | - OT was effective in most patients with PCOD in clinically improving OF  
- Training for longer than 28 days may lead to improved outcomes  
- Hyposmic patients had improved prognosis than anosmic patients |
| Studies on PVOD/PIOD       |                  |                                                                             |                                                                                                                                                                                                         |                                                                                                                                                                                                           |
| Hura et al. 2020 [13•]     | 1a               | - Systematic review of OT outcomes among patients with PVOD  
- 10 studies analyzed, including 2 large RCTs (level 1b), 2 small RCTs (level 2b), 3 prospective cohort studies (level 3), and 3 prospective/retrospective case series (level 4 studies) | - OT resulted in improved TDI and UPSIT scores  
- Minimal adverse effects (inconvenience of daily training) were seen | - OT for a minimum of 12 weeks is a recommendation for treatment of PVOD. OT is an inexpensive option with minimal/no harm and high benefit |
| Study/year          | Level of evidence | Study design                                                                 | Results                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Conclusions                                                                                                                                                                                                                                                                                                                                 |
|--------------------|-------------------|------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Kattar et al. 2021 | 2a                | Systematic review of OT outcomes among patients with PVOD                    | - Nearly threefold greater odds of achieving a clinically significant improvement in TDI scores among patients undergoing OT compared to controls (OR 2.77; 95% CI 1.67–4.58), even after accounting for variability in OT protocols among the 4 studies  
- Longer durations of OT (up to 56 weeks), along with shorter durations of symptoms prior to initiation of OT (< 12 months), were associated with greater improvements in olfactory function                                                                                                                                 | - OT for a minimum of 12 weeks improved olfactory function, among patients with PVOD  
- The strengths of OT included ease of implementation and minimal adverse effects  
- The limitations of OT included a lack of consensus regarding the optimal duration of therapy, dependence on high patient compliance (sustained daily training for months), and long-term effectiveness of therapy (>56 weeks)                                                                                                                                                                |
| Addison et al. 2021| 2A               | Meta-analysis of 40 studies, including 11 RCTs investigating PIOD             | - OT had significant evidence of benefit for patients with generalized anosmia                                                                                                                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                                                                                                     |
| Study/year                  | Level of evidence | Study design | Results                                                                 | Conclusions                                                                 |
|---------------------------|-------------------|--------------|--------------------------------------------------------------------------|-----------------------------------------------------------------------------|
| Hummel et al. 2017 [26]   | 5                 | -Position paper | -Review of 6 studies demonstrated that OT led to improve OF after 12–36 weeks of treatment, with longer durations of treatment and higher odor concentrations resulting in greater improvements in OF -OT was postulated to increase regenerative capacity of olfactory neurons as a result of repeated odorant exposure | -Given low cost and high safety of OT, it was recommended in patients with OD of several etiologies |

CI confidence interval  
OD olfactory dysfunction  
OF olfactory function  
OR odds ratio  
OT olfactory training  
PCOD post-COVID-19 olfactory dysfunction  
PIOD post-infectious olfactory dysfunction  
PVOD post-viral olfactory dysfunction  
RCT randomized controlled trial  
TDI score threshold, discrimination, and identification score  
UPSIT University of Pennsylvania Smell Identification Test
improved TDI and UPSIT scores, concluding that a minimum of 12 weeks of therapy was recommended for treatment of PVOD [13•], level 1A]. Addison et al. reviewed 40 studies – of which 11 were RCTs – and published similar findings, demonstrating that long-term OT (>32 weeks) with high-concentration odorants conferred significant benefit for patients with generalized anosmia [19••], level 2A]. Kattar et al. reviewed 4 studies including 2 RCTs, concluding that there was a threefold greater chance of achieving a clinically significant improvement in TDI scores among patients undergoing OT compared to controls. This finding also held true after accounting for variability in OT protocols. Additionally, this systematic review found that longer duration of OT (up to 56 weeks) along with earlier initiation of OT following symptoms (<12 months) was associated with greater improvements in olfactory function [14••], level 2A]. Kattar et al., however, acknowledged the current limitations to OT, including a lack of consensus regarding optimal duration of therapy, dependence on high patient compliance, and need for long durations of treatment to achieve therapeutic effect.

Nevertheless, given its limited harm profile, relatively low cost, and evidence of effectiveness, patients should begin OT as soon as possible following symptoms of PCOD and continue therapy for a minimum of 12 weeks [19••, 29], level 2A].

Pharmacologic Treatment

While most cases of PCOD resolve spontaneously within 2 weeks, cases that persist beyond this timepoint may require pharmacologic intervention. Recent MRI studies have demonstrated inflammatory changes in the olfactory clefts of COVID-19 patients with anosmia compared to healthy controls, suggesting a possible role for anti-inflammatory agents such as intranasal corticosteroid sprays and oral corticosteroids [25], level 4]. A position paper by Hummel et al. recommended use of systemic and/or topical steroids in patients with olfactory dysfunction secondary to chronic rhinosinusitis and other inflammatory conditions, also suggesting a role for steroid treatments for PCOD [26], level 5].

Intranasal Corticosteroid Sprays

There is conflicting evidence regarding the efficacy of intranasal corticosteroid sprays (ICS), with some RCTs showing no benefit [18], level 2B], and others demonstrating improvement in olfaction scores following short-term courses of ICS therapy [16, 30], level 2B] [Table 2].

In one of the few RCTs published studying PCOD patients, Abdelalim et al. [18], level 1B] performed a study of 50 individuals who underwent daily mometasone furoate nasal sprays in combination with OT for 3 weeks, compared to 50 patients who underwent OT alone. Patients who underwent added MFNS therapy experienced no significant benefit over OT alone, as
| Study/year | Level of evidence | Study design | Results | Conclusions |
|------------|------------------|--------------|---------|-------------|
| **Studies on PCOD** | | | | |
| Abdelalim et al. 2021 [18] | 1b | - RCT of 50 patients with PCOD who underwent daily MFNS with OT, compared to 50 patients who underwent OT alone, for 3 weeks - Olfactory function was assessed using the VAS. Duration of anosmia was recorded from onset until full recovery. Recovery rates were recorded - Follow-up time was 3 weeks | - VAS smell scores significantly improved in both groups by the 3rd week of treatment ($P<0.001$). There were no significant differences between the groups after 1, 2, or 3 weeks of treatment - The average time until complete recovery in the MFNS + OT group was 26.4 days, compared to 26.2 days in the OT alone group ($P=0.88$) - 62% of patients who underwent MFNS + OT completely recovered their sense of smell after 3 weeks, compared to 52% of patients who underwent OT alone ($P=0.31$) | - Adding MFNS in the treatment of PCOD offers no superiority benefit over OT, regarding VAS smell scores, duration of anosmia, and recovery rates |
| Hopkins et al. 2021 [15] | 5 | - Expert consensus statement based on literature review conducted via Medline and Cochrane databases | - Consensus of 15 experts agreeing that topical intranasal corticosteroids might aid in PCOD | - ICS is recommended in patients with anosmia lasting longer than 2 weeks |
| Singh et al. 2021[30] | 3B | - Prospective interventional study of 120 patients with PCOD - OF tested at days 1 and 5 after positive RT-PCR - 60 patients given 2 sprays fluticasone every day for 5 days | - Symptoms of anosmia and dysgeusia improved for patients receiving ICS over those in the control group ($p<0.001$) | - In the acute setting, ICS may hasten recovery; however, it is unclear whether these patients would have recovered OF eventually or whether early intervention prevented long-term anosmia given lack of long-term follow-up |
| **Studies on PVOD/PIOD** | | | | |
| Study/year                | Level of evidence | Study design                                                                 | Results                                                                                                                                                                                                 | Conclusions                                                                                                                                                                                                 |
|--------------------------|-------------------|------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Hura et al. 2020 [13•]  | 3a                | - Systematic review of PVOD undergoing treatment with ICS                    | - Some patients (25–58%) with PVOD demonstrated mildly improved olfactory scores after use of ICS                                                                                                         | - Short-term ICS use is an option for management of PVOD due to the mild benefit seen in some patients and overall low risk of therapy. If there is no initial improvement after ICS use, then there is limited evidence suggesting benefit with chronic use |
|                          |                   | - Studies analyzed included 1 RCT (level 1b), 1 case series (level 4), and 1 retrospective review (level 4) | - Minimal side effects (local irritation, epistaxis) were seen with ICS                                                                                                                                  |                                                                                                                                                                                                          |
|                          |                   | - The RCT included 23 patients who were initially treated with a 10-day course of OCS + ICS, after which they were randomized to continue ICS versus placebo versus control. All patients experienced improvement in olfactory scores after the initial 10-day treatment period. Given co-treatment, this improvement may not be attributed to ICS alone. Patients taking ICS compared to placebo or control showed no difference in olfactory outcomes at 6-month follow-up |                                                                                                                                                                                                          |                                                                                                                                                                                                          |
|                          |                   | - The level 4 studies lacked control groups; therefore, it was difficult to determine whether recovery of olfaction was due to spontaneous recovery or the effect of treatment |                                                                                                                                                                                                          |                                                                                                                                                                                                          |
| Study/year          | Level of evidence | Study design                                                                 | Results                                                                                                                                                                                                 | Conclusions                                                                                                                                                                                                 |
|---------------------|-------------------|------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Addison et al. 2021 [19**] | 2A                | Meta-analysis of 40 studies, including 11 RCTs investigating PIOD            | - 1 prospective case series showing benefit of ICS in 2 of 8 patients  
- 1 prospective study showing intranasal injection leading to 50% improvement  
- 1 observational study using topical steroids with 58% self-reporting improvement in symptoms  
- Studies examined were mostly conducted on PVOD patients before COVID-19 pandemic and may not be specific to PCOD | - ICS may alleviate symptoms in patients without spontaneous improvement in olfaction  
- Kaiteki position in which patients lie on the side with their head tilted may have more efficacy by allowing nasal drops to reach the olfactory cleft |

ICS intranasal corticosteroid spray  
MFNS mometasone furoate nasal sprays  
OCS oral corticosteroid  
OF olfactory function  
OT olfactory training  
PCOD post-COVID-19 olfactory dysfunction  
PICD post-infectious olfactory dysfunction  
PVOD post-viral olfactory dysfunction  
RCT randomized controlled trial  
VAS visual analog scale
measured by smell scores, duration of anosmia, and recovery rates. However, the time since onset of OD symptoms was not standardized among the patients of this study. Given that patients experience variable recovery depending on the time of therapy initiation after infection, this study does not exclude the possibility of a subset of patients that, when treated early in their clinical course, might benefit from ICS.

Several consensus statements have recommended ICS for patients with PCOD symptoms lasting longer than 2 weeks [15, level 5; 19••, level 2A]. Hopkins et al. reported the consensus statement of the British Rhinological Society, integrating information from a literature review of post infectious olfactory dysfunction graded by 15 experts [15, level 5]. Multiple studies reviewed by Hopkins et al. demonstrated no additive benefit to topical steroids when used in combination with oral steroids. However, another retrospective study cited by Hopkins et al. noted combination of ICS with olfactory training was more therapeutic than olfactory training alone. Ultimately, Hopkins et al. recommended ICS for PCOD symptoms persisting past 2 weeks [19••], level 2A).

Interestingly, one study reported by Hopkins et al. demonstrated a benefit with budesonide irrigations, leading the authors to suggest that sufficient contact of areas of inflammation was necessary to achieve therapeutic effect [19••], level 2A). In a similar vein, some authors have suggested that nasal irrigation, rather than sprays, may be more effective at treating PCOD due to increased penetration to the olfactory cleft [31], level 2B]. To this end, some have suggested the use of the Kaiteki position, wherein patients lay on their side with the head tilted and chin lifted at a 20 to 40 degree angle, such that nasal drops may reach the olfactory cleft [32], level 4].

Addison et al. reported on the consensus statement of the Clinical Olfactory Working Group based on 15 articles evaluating management of post-infectious olfactory dysfunction [19••], level 2A]. This group concluded that, though direct evidence of the utility of ICS was limited, the relative risk of ICS was low enough such that a trial of ICS was advisable for most patients. Like the studies analyzed by Hopkins et al., many of the papers analyzed by Addison et al. tested the efficacy of ICS in combination with other therapies. As such, there has been limited evidence of the use of ICS alone. Importantly, Addison et al. concurred with Hopkins et al. in concluding that effective delivery of topical corticosteroids could play a limiting factor in the efficacy of ICS and suggested that patients might benefit from usage of the Kaiteki position [19••], level 2A].

A systematic review by Hura et al. included three studies that looked into the utility of topical corticosteroid sprays, of which one was a RCT performed by Blomqvist et al. in 2003 among patients with post-viral olfactory dysfunction [13•], level 1A]. In this RCT, 23 patients were treated with a 10-day course of ICS and oral corticosteroids (OCS), after which they were randomized to continued ICS, placebo, or control groups. The study demonstrated no differences in outcome in olfactory function at 6 months among the three groups, suggesting limited benefit in chronic use of ICS. However, in two other case series analyzed by Hura et al., topical application of corticosteroids was investigated and found to cause some improvement in olfactory dysfunction. Though this effect was only seen in a subset of patients (25–58%), Hura
et al. concluded that the limited side effects of topical corticosteroids and the possibility of therapeutic effect made ICS preferable to oral corticosteroids for many patients [13•], level 1A.

In summary, though the evidence to support use of ICS in PCOD patients is mixed both in strength and applicability to post-SARS-CoV2 patients, the side effect profile of this therapy is limited; as such, for most patients, the potential benefits likely outweigh the risks for a short-term trial. Drug information for intranasal corticosteroids is provided in Table 3.

### Oral Corticosteroids

There is limited evidence to support the use of oral corticosteroids (OCS) in PCOD [Table 4]. Consensus statements published by Hopkins et al. and Addison et al. advised that, though OCS have evidence of effectiveness, they have a limited role in routine clinical management of PCOD due to their extended side effect profile [15], level 5; 19••, level 2A]. One retrospective study analyzed by Addison et al. was performed on patients with any cause of olfactory dysfunction and showed the combination of OCS + ICS or OCS alone was more effective at treating PCOD than ICS alone [19••], level 2A]. The consensus statement released by Addison et al. also discussed an RCT in which patients with post-infectious olfactory dysfunction were initially treated with oral prednisolone before transitioning to ICS. This investigation found that the initial course of oral steroids was effective at reducing PCOD symptoms, while the subsequent course of topical steroids conferred no additional advantage [19••], level 2A]. Another study included by Addison et al. showed an oral methylprednisolone taper was able to improve olfactory dysfunction of all etiologies [19••], level 2A]. However, these studies were all limited by lack of specificity to PCOD. Moreover, several studies reported by Addison et al. were performed on patient populations with olfactory dysfunction of non-infectious origins and thus cannot be readily generalizable to the PCOD patient set. Both consensus statements published by Addison et al. and Hopkins et al. agreed that, due to the multi-system nature of

| Table 3 Drug information for intranasal corticosteroids |
|--------------------------------------------------------|
| **Mometasone furoate or fluticasone propionate**         |
| **Standard dosage** | 2 sprays (100ug) of mometasone or fluticasone daily in each nostril for 3 weeks |
| **Contraindications** | Current or past tuberculosis, infections of any type (virus, bacteria, fungus, amoeba), glaucoma, cataracts, nasal ulcers |
| **Main drug interactions** | None |
| **Main side effects** | Nasal/throat irritation, dryness, epistaxis |
| **Special points** | Differences in the type, dosing, and duration of intranasal corticosteroid sprays vary among studies |
| **Cost/cost-effectiveness** | $30–$60 per month |
| Study/year | Level of evidence | Study design | Results | Conclusions |
|------------|-------------------|--------------|---------|-------------|
| Le Bon et al. 2021 [17] | 2b | Non-randomized prospective controlled trial of 9 COVID-19 patients undergoing a 10-day course of OCS + OT, compared to 18 COVID-19 patients undergoing OT alone | - Greater improvement in TDI score among patients undergoing OCS + OT, compared to OT alone ($P=0.046$) - The authors reported a low level of compliance for OT (<50%) - 3 patients reported mild side effects to OCS including abdominal pain and insomnia | - This pilot study suggests a combination of OCS + OT is safe and beneficial for treatment of PCOD, compared to OT alone |
| Vaira et al. 2020 [16] | 2B | Non-randomized RCT with 18 patients with PCOD for more than 30 days - 9 patients treated with systemic prednisone and nasal irrigation with becatamethasone for 15 days - 9 patients were otherwise untreated | - Patients showed no improvement at 20 days - Treatment group had greater improvement in olfactory scores at 40 day evaluations - Study limited by small sample size and unevenly distributed treatment groups | - Refractory anosmia may respond to combination of ICS and OCS - Treatment difference may manifest weeks after initial therapy |
| Huart et al. 2021 [29] | 2A | Delphi process performed on experts from the Clinical Olfaction Working Group | - General efficacy of OCS remains controversial; evidence to support OCS is level 4 - OCS may potentially inhibit neuronal regeneration of olfactory epithelium | - Selected patients may benefit from systemic corticosteroids given signs of nasal inflammation - There is a lack of evidence of clear benefit for patients taking OCS, and they should be used with caution according to patient circumstances |

**Studies on PVOD/PIOD**
| Study/year | Level of evidence | Study design | Results | Conclusions |
|------------|------------------|--------------|---------|-------------|
| Hura et al. 2020 [13•] | 3a | Systematic review of OCS in management of PVOD - 6 studies analyzed, including 1 prospective case–control study (level 3b) and 5 retrospective reviews (level 4) | - Short-term (~2 weeks with taper) OCS resulted in mildly improved olfactory scores across multiple psychophysical tests, at a cost of potential side effects related to OCS - Studies lacked control groups; therefore, it was difficult to determine whether recovery of olfaction was due to spontaneous recovery or the effect of treatment - A retrospective review by Kim et al. with 491 patients demonstrated that patients taking MFNS alone were less likely to recover olfactory function (28.2% recovery rate), compared to those taking oral prednisolone with MFNS (54.8% recovery rate) or those taking oral prednisolone alone (55.0% recovery rate) after 1-month follow-up ($P<0.001$) - A retrospective review by Schriever et al. showed a significant increase in TDI score ($P=0.003$) after 2 weeks of oral methylprednisolone treatment, although there was no control group and the increase in TDI score failed to reach the minimal clinically importance difference | - Short-term OCS (~2 weeks with taper) are an option in select patients with PVOD, after consideration of the potential risks of oral steroids in the setting of medical comorbidities |
| Study/year          | Level of evidence | Study design                                                                 | Results                                                                                                                                                                                                 | Conclusions                                                                                                                                                        |
|--------------------|-------------------|------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Addison et al. 2021 [19**] | 2A                | Meta-analysis of 40 studies, including 11 RCTs investigating PIOD             | Retrospective study showing improvement of OD with OCS and combination OCS with ICS, over ICS alone in general OD  
|                    |                   |                                                                              | - RCT showing 40 mg prednisolone can lead to improve OF in PVOD  
|                    |                   |                                                                              | - Oral methylprednisolone 40 mg showed improvement in general OD  
|                    |                   |                                                                              | - Observational study showing no improvement in patients given oral prednisolone after failing ICS in general OD | Oral corticosteroids may show some efficacy in PCOD patients as they have shown some success in improving anosmia in post-infectious OD  
|                    |                   |                                                                              | | Patients who have failed ICS may not respond to OCS |

*MFNS* mometasone furoate nasal sprays  
*OCS* oral corticosteroids  
*OD* olfactory dysfunction  
*OT* olfactory training  
*PCOD* post-COVID-19 olfactory dysfunction  
*PIOD* post-infectious olfactory dysfunction  
*PVOD* post-viral olfactory dysfunction  
*TDI score* threshold, discrimination, and identification score
SARS-CoV2, multidimensional risk benefit analysis should occur before initiation of oral steroid therapy. However, Hopkins et al. stated that a short trial of oral corticosteroids could be appropriate in the scenario where olfactory dysfunction is the only symptom of SARS-CoV2 [19••], level 2A.

Several studies exist examining the effect of oral steroids more specifically in PCOD patients. A non-randomized controlled trial by Le Bon et al. [17], level 2B showed greater improvements in olfactory scores among PCOD patients undergoing OCS and olfactory training (OT), compared to OT alone. However, this trial studied 27 patients, of which only 9 were treated with oral corticosteroids, thereby limiting its statistical power. Vaira et al. reported on a non-randomized control trial testing the efficacy of the combination of systemic prednisone and ICS in patients with PCOD persisting longer than 30 days. This study found significant improvement at 40 days of treatment, suggesting that long-term courses of OCS and intranasal steroid irrigation could prove useful for refractory cases [8], level 2B.

Hura et al. aggregated six studies of OCS to show that patients experienced quantifiable improvement in olfaction, but concluded that consideration of OCS was patient- and situation-dependent, given the broad side effect profile [13•], level 3A. Similarly, Addison et al. stated that while OCS had some evidence of clinical utility, clinicians were divided on its routine use in a PCOD setting; the authors suggested the alternative of a short 3–4-day course of OCS to trial therapy responsiveness before beginning a more prolonged course [19••], level 2A.

Ultimately, though the side effect profile limits its applicability, evidence suggests OCS may be an effective option in some patients with persistent PCOD symptoms. Furthermore, several trials in the literature suggest the

| Table 5 Drug information for oral corticosteroids |
|-----------------------------------------------|
| **Oral prednisolone**                         |
| **Standard dosage**                          |
| Option 1) 30 mg/day × 3 days, followed by 20 mg/day × 4 days, followed by 10 mg/day × 7 days |
| OR Option 2) 40 mg/day × 14 days, followed by a taper (daily reduction of 5 mg) |
| **Contraindications**                        |
| Diabetes, hypertension, kidney disease, cardiovascular disease, liver disease, under- or over-active thyroid, neuropsychiatric disease, osteoporosis or any other bone disease, stomach or intestine problems, current or past tuberculosis, infections of any type (virus, bacteria, fungus, amoeba), myasthenia gravis, glaucoma, cataracts, mental disorders, pregnancy |
| **Main drug interactions**                   |
| Mifepristone, drugs that can cause bleeding/bruising (aspirin, coumadin), other systemic corticosteroids, immunosuppressants, immune modulators, certain antibiotics, antiseizure medications, anticholinesterase medications |
| **Main side effects**                        |
| Nausea/vomiting, heartburn, headache, dizziness, menstrual period changes, insomnia, fatigue, weight gain, fluid retention, hypertension, cataracts, glaucoma, easy bruising/bleeding, acne, reduced immune response and ability to fight infections, adrenal suppression, hyperglycemia, mental/mood changes, muscle weakness/pain, skin thinning, slow wound healing, bone pain or fractures, stomach/intestinal bleeding, trouble breathing, seizures |
| **Special points**                           |
| Differences in the type, dosing, and duration of oral corticosteroids vary among studies |
| **Cost/cost-effectiveness**                  |
| Inexpensive ($10–20 per course)              |
combination of OCS and ICS may prove useful for refractory cases of olfactory dysfunction. Drug information for oral corticosteroids is provided in Table 5.

Declarations

Conflict of Interest
The authors declare no competing interests.

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as:
• Of importance
•• Of major importance

1. Moein ST, Hashemian SM, Mansourafshar B, Khorram-Tousi A, Tabarsi P, Doty RL. Smell dysfunction: a biomarker for COVID-19. Int Forum Allergy Rhinol. 2020;10:944–50.
2. Lechien JR, Chiesa-Estomba CM, De Siat DR, Horoi M, Le Bon SD, Rodriguez A, et al. Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study. Eur Arch Otorhinolaryngol. 2020;277:2251–61.
3. Bilinska K, Butowt R. Anosmia in COVID-19: a bumpy road to establishing a cellular mechanism. ACS Chem Neurosci. 2020;11:2152–5.
4. Xu H, Zhong L, Deng J, Peng J, Dan H, Zeng X, et al. High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa. Int J Oral Sci. 2020;12:1–5.
5. Roy D, Ghosh R, Dubey S, Dubey MJ, Benito-León J, Ray BK. Neurological and neuropsychiatric impacts of COVID-19 pandemic. Can J Neurol Sci. 2020;00:1–16.
6. Laurendon T, Radulesco T, Mugnier J, Géralt M, Chagnaud C, El Ahmadi AA, et al. Bilateral transient olfactory bulb edema during COVID-19–related anosmia. Neurology. 2020;95(5):224–5.
7. Giacomelli A, Pezzati L, Conti F, Bernacchia D, Siano M, Oreni L, et al. Self-reported olfactory and taste disorders in patients with severe acute respiratory coronavirus 2 infection: a cross-sectional study. Clin Infect Dis. 2020;71(15):889–90.
8. Vaira LA, Salzano G, Deiana G, De Riu G. Anosmia and Ageusia: Common Findings in COVID-19 Patients. Laryngoscope. 2020;130:1787.
9. Klopfenstein T, Kadiane-Oussou NJ, Toko L, Royer PY, Lepiller Q, Gendrin V, et al. Features of anosmia in COVID-19. Med Mal Infect. 2020;50:436–9.
10. Orsucci D, Ienco EC, Nocita G, Napolitano A, Vista M. Neurological features of COVID-19 and their treatment: a review. Drugs Context. 2020;9:2020-5-1.
11. Mendelson M, Nel J, Blumberg L, Madhi SA, Dryden M, Stevens W, et al. Long-COVID: an evolving problem with an extensive impact. S Afr Med J. 2021;111(1):10–2.
12. Pekala K, Chandra RK, Turner JH. Efficacy of olfactory training in patients with olfactory loss: a systematic review and meta-analysis. Int Forum Allergy Rhinol. 2016;6:299–307.
13. Hura N, Xie DX, Choby GW, Schlosser RJ, Orlov CP, Seal SM, et al. Treatment of post-viral olfactory dysfunction: an evidence-based review with recommendations. Int Forum Allergy Rhinol. 2020;10:1065–86. This is a systematic review of 10 studies including 4 RCTs investigating PVOD, which showed mild benefit with use of ICS and OCS and significant benefit with OT.
14. Kattar N, Do TM, Unis GD, Mignerone MR, Thomas AI, McCoult ED. Olfactory training for postviral olfactory dysfunction: systematic review and meta-analysis. Otolaryngol Head Neck Surg. 2021;164:244–54. This is a meta-analysis of 4 studies, including 2 RCTs, investigating OT outcomes in PVOD, demonstrating a 3-fold greater odds of a clinically significant improvement in olfactory function with OT compared to controls.
15. Hopkins C, Alanin M, Philpott C, Harries P, Whitcroft K, Qureishi A, et al. Management of new onset...
loss of sense of smell during the COVID-19 pandemic-BRS Consensus Guidelines. Clin Otolaryngol. 2021;46(1):16–22.

16. Vaira LA, Deiana G, Fois AG, Pirina P, Madeddu G, De Vito A, et al. Objective evaluation of anosmia and ageusia in COVID-19 patients: single-center experience on 72 cases. Head Neck. 2020;42(6):1252–8.

17. Le Bon SD, Konopnicki D, Pisarski N, Prunier L, Lechien JR, Horoi M. Efficacy and safety of oral corticosteroids and olfactory training in the management of COVID-19-related loss of smell. Eur Oto-Rhinolaryngol. 2021;278(8):3113–3117.

18. Abdelalim AA, Mohamady AA, Elsayed RA, Elawady MA, Ghallab AF. Corticosteroid nasal spray for recovery of smell sensation in COVID-19 patients: a randomized controlled trial. Am J Otolaryngol. 2021;42(2):102884.

19. Addison AB, Wong B, Ahmed T, Macchi A, Konstantinidis I, Huart C, et al. Clinical Olfactory Working Group consensus statement on the treatment of postinfectious olfactory dysfunction. J Allergy Clin Immunol. 2021;147(5):1704–19. This is a meta-analysis of 40 studies, including 11 RCTs investigating PVOD, which showed mild benefit with use of ICS and OCS and significant benefit with OT.

20. Hummel T, Risson K, Reden J, Hahner A, Weidenbecher M, Huttenbrink KB. Effects of olfactory training in patients with olfactory loss. Laryngoscope. 2009;119:496–9.

21. Doty RL, Shamar P, Kimmelman CP, Dann MS. University of Pennsylvania Smell Identification Test: a rapid quantitative olfactory function test for the clinic. Laryngoscope. 1984;94:176–8.

22. Cain WS, Gent JF, Goodspeed RB, Leonard G. Evaluation of olfactory dysfunction in the Connecticut Chemosensory Clinical Research Center. Laryngoscope. 1988;98:83–8.

23. McCormack HM, Horne DJ, Sheather S. Clinical applications of visual analogue scales: a critical review. Psychol Med. 1988;18:1007–19.

24. Desai M, Oppenheimer J. The Importance of Considering Olfactory Dysfunction During the COVID-19 Pandemic and in Clinical Practice. J Allergy Clin Immunol Pract. 2021;9(1):7–12.

25. Altundag A, Yildirim D, Tekcan-Sanli DE, Cayonu M, Kandemirli SG, Sanli AN, et al. Olfactory Cleft Measurements and COVID-19-Related Anosmia. Otolaryngol Head Neck Surg. 2021;164(6):1337–44.

26. Hummel T, Whitcroft KL, Andrews P, Altundag A, Cinghi C, Costanzo RM, et al. Position paper on olfactory dysfunction. Rhinol Suppl. 2017;54:1–30.

27. Denis E, Septans AI, Periers L, Maillard JM, Legoff E, Gurden H, et al. Olfactory training and visual stimulation assisted by a web application for patients with persistent olfactory dysfunction after SARS-COV-2 infection: observational study. J Med Internet Res. 2021;23(5):29583.

28. Patel ZM, Wise SK, DelGaudio JM. Randomized controlled trial demonstrating cost-effective method of olfactory training in clinical practice: essential oils at uncontrolled concentration. Laryngoscope Investig Otolaryngol. 2017;2:53–6.

29. Huart C, Philpott CM, Altundag A, Fjaeldstad AW, Frasnelli J, Gane S, et al. Systemic corticosteroids in coronavirus disease 2019 (COVID-19)-related smell dysfunction: an international view. Int Forum Allergy Rhinol. 2021;11(7):1041–6.

30. Singh CV, Jain S, Parveen S. The outcome of fluticasone nasal spray on anosmia and triamcinolone oral paste in dysgeusia in COVID-19 patients. Am J Otolaryngol. 2021;42(3):102892.

31. Nguyen TP, Patel ZM. Budesonide irrigation with olfactory training improves outcomes compared with olfactory training alone in patients with olfactory loss. Int Forum Allergy Rhinol. 2018;8(9):977–81.

32. Mori E, Merkonidis C, Cuevas M, Guzdiol V, Matsuwaki Y, Hummel T. The administration of nasal drops in the “Kaiteki” position allows for delivery of the drug to the olfactory cleft: a pilot study in healthy subjects. Eur Arch Otorhinolaryngol. 2016;273(4):939–43.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.